Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.42 USD | +1.74% | -0.93% | +3.55% |
Apr. 17 | Wedbush Raises Price Target on Ardelyx to $14 From $13, Keeps Outperform Rating | MT |
Apr. 05 | Leerink Partners Initiates Coverage on Ardelyx With Outperform Rating, $14 Price Target | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- Low profitability weakens the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+3.55% | 1.49B | B | ||
-2.31% | 103B | B+ | ||
+0.56% | 95.28B | B+ | ||
+1.69% | 22.15B | B | ||
-17.37% | 21.02B | B+ | ||
-9.30% | 18.15B | A- | ||
-41.01% | 16.74B | A- | ||
-14.85% | 16.05B | B | ||
+3.21% | 13.68B | C+ | ||
+33.54% | 12.17B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ARDX Stock
- Ratings Ardelyx, Inc.